摘要
AIM: To investigate the clinical performances of rapidstool test (ImmunoCard STAT HpSA, Meridian DiagnosticInc.) in the evaluation of eradication therapy of H pyloriand to compare it with a well-known and validatedlaboratory stool test (Amplified IDEA Hp StAR, Dako).METHODS: Stool samples of 122 patients wereevaluated after eradication therapy of H pylori. H pyloristatus was assessed by 13C-urea breath test (UBT).Stool specimens were tested using either the rapidimmunoassay kit or the laboratory immunoassay kit.RESULTS: Forty-three patients were infected and 79non-infected. Sensitivity and specificity of ImmunoCardSTAT and Hp StAR were 58.14% and 76.4%, and97.47% and 98.73%, respectively (P > 0.05). Overallagreement between the two tests was 92.6% (113 of122 cases).CONCLUSION: ImmunoCard STAT seems to haverather low performances, and it cannot be regarded as areliable tool in the post-treatment setting. Also Hp StARcannot be recommended to confirm H pylori eradicationafter treatment.
AIM： To investigate the clinical performances of rapid stool test （ImmunoCard STAT HpSA, Meridian Diagnostic Inc.） in the evaluation of eradication therapy of Hpylori and to compare it with a well-known and validated laboratory stool test （Amplified IDEA Hp STAR, Dako）. METHODS： Stool samples of 122 patients were evaluated after eradication therapy of H pylori. H pylori status was assessed by 13C-urea breath test （UBT）. Stool specimens were tested using either the rapid immunoassay kit or the laboratory immunoassay kit. RESULTS： Forty-three patients were infected and 79 non-infected. Sensitivity and specificity of ImmunoCard STAT and Hp StAR were 58.14% and 76.4%, and 97.47% and 98.73%, respectively （P 〉 0.05）. Overall agreement between the two tests was 92.6% （113 of 122 cases）. CONCLUSION： ImmunoCard STAT seems to have rather low performances, and it cannot be regarded as a reliable tool in the post-treatment setting. Also Hp StAR cannot be recommended to confirm Hpylori eradication after treatment.
